Risk factor
Very high price volatility
Profitability factor
Very low or no dividends
About
Headquartered in Seoul, South Korea, Gencurix Inc. has been developing and providing advanced diagnostic solutions since its establishment in 2011. The company's comprehensive product lineup addresses various medical needs. For cancer diagnostics, offerings include GenesWell BCT, a prognostic test for breast cancer; the GenesWell ddEGFR Mutation Test, a companion diagnostic for lung cancer; Droplex, which detects DNA mutations; and eDX, facilitating early cancer detection via liquid biopsy. In the realm of infectious diseases, Gencurix provides the GenePro COVID-19 detection test and GenePro SARS-CoV-2 Test kit. Additionally, their portfolio features the GenoCTC, a circulating tumor cell isolator, alongside the GenePro LAMP test solution for quick and straightforward detection of numerous infectious agents, supported by the GenePro LAMP Cycler device for loop-mediated isothermal amplification.
Company Valuation
Considering past and projected metrics, the stock is neither 'expensive' nor 'cheap' compared to its peers.